Acorn Capital Advisors, LLC

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Acorn Capital Advisors, LLC reported 20 stock positions worth $366.5 million. Its top holding was CG Oncology (CGON) at 21.9% of the portfolio, followed by Urogen Pharma (URGN, 16.8%) and Trevi Therapeutics (TRVI, 10.9%). Compared with Q1 2026, it opened 1 new position, sold out of 3, added to 5 and reduced 3. The biggest buy was Karyopharm Therapeutics (KPTI, shares +427%) and the biggest sale an exit from Terns Pharmaceuticals (TERN).

Most Recent 13F
Q2 2026
Location
NEW YORK, NY
CIK
0002054410
Portfolio Value
$366.5M (Q2 2026)
SEC Filing
0001636587-26-000067 ↗ filed Aug 14, 2026

Holdings Value

0$100.0M$200.0M$300.0M$400.0M Q4 2024: $185.8M Q4 2024 Q1 2025: $149.9M Q1 2025 Q2 2025: $152.9M Q2 2025 Q3 2025: $197.0M Q3 2025 Q4 2025: $295.1M Q4 2025 Q1 2026: $351.8M Q1 2026 Q2 2026: $366.5M $366.5M Q2 2026

Holdings 20 stocks · $366.5M
CGON CG Oncology Inc. 21.94% 1,131,500 $80.4M Add +0.1%
URGN Urogen Pharma Ltd. 16.80% 1,673,420 $61.6M No change
TRVI Trevi Therapeutics Inc. 10.92% 2,144,844 $40.0M No change
CADL Candel Therapeutics Inc. 9.83% 3,497,948 $36.0M No change
PBYI Puma Biotechnology Inc. 9.14% 4,131,299 $33.5M No change
JBIO Jade Biosciences Inc. 5.98% 986,760 $21.9M Add +25.4%
BCAX Bicara Therapeutics Inc. 5.21% 643,381 $19.1M Reduce 0.0%
KPTI Karyopharm Therapeutics Inc. 4.05% 1,518,113 $14.8M Add +427.4%
OKUR Onkure Therapeutics Inc. Class A 3.53% 2,839,674 $12.9M No change
HELP Cybin Inc. 2.78% 1,540,266 $10.2M No change
TARA Protara Therapeutic Inc. 1.83% 1,752,115 $6.7M No change
AURA Aura Biosciences Inc. 1.80% 929,077 $6.6M Add +56.0%
LONA Leonabio Inc. 1.59% 634,539 $5.8M No change
VSTM Verastem Inc. 1.53% 1,469,153 $5.6M No change
WHWK Whitehawk Therapeutics Inc. 1.42% 1,139,363 $5.2M No change
QTTB Q32 Bio Inc. 0.75% 216,171 $2.8M Reduce -31.4%
ENGN Engene Therapeutics Inc. 0.60% 1,271,257 $2.2M New
JSPR Jasper Therapeutics Inc. 0.16% 1,438,159 $604K Add +1.9%
BCAB Bioatla Inc. 0.12% 108,126 $448K Reduce -98.0%
VYNE THERAPEUTICS INC 0.00% 1,425 $926 No change

Portfolio Sells Q1 2026 → Q2 2026
TERN Terns Pharmaceuticals Inc. Sold out 0.00% −26.17
CRDF Cardiff Oncology Inc. Sold out 0.00% −0.81
XFOR X4 Pharmaceuticals Inc. Sold out 0.00% −0.27
BCAB Bioatla Inc. Reduce -98.0% 0.12% −0.12
QTTB Q32 Bio Inc. Reduce -31.4% 0.75% +0.18
BCAX Bicara Therapeutics Inc. Reduce 0.0% 5.21% +1.58

Portfolio Buys Q1 2026 → Q2 2026
KPTI Karyopharm Therapeutics Inc. Add +427.4% 4.05% +3.59
JBIO Jade Biosciences Inc. Add +25.4% 5.98% +2.84
AURA Aura Biosciences Inc. Add +56.0% 1.80% +0.67
ENGN Engene Therapeutics Inc. New 0.60% +0.60
CGON CG Oncology Inc. Add +0.1% 21.94% +0.17
JSPR Jasper Therapeutics Inc. Add +1.9% 0.16% −0.19

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 20$366.5MCGON, URGN, TRVI, CADL, PBYI
Q1 2026 22$351.8MTERN, CGON, URGN, PBYI, TRVI
Q4 2025 21$295.1MTERN, CGON, URGN, TRVI, PBYI
Q3 2025 20$197.0MCGON, URGN, PBYI, TRVI, TERN
Q2 2025 21$152.9MCGON, URGN, YMAB, PBYI, CADL
Q1 2025Amended 22$149.9MCGON, URGN, YMAB, TRVI, CADL
Q4 2024Amended 21$185.8MCGON, YMAB, CADL, URGN, PBYI